Clinical Trial Update: Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS [Phase 2]

View source ↗

Summary

Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study evaluating SSR149744c at 100 mg or 300 mg for the prevention of ventricular arrhythmia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ventricular Arrhythmia
• Ventricular Fibrillation
• Ventricular Tachycardia

Drugs mentioned

• SSR149744c (SSR149744c)

Snippet

Sponsor: Sanofi | Conditions: Arrhythmia, Tachycardia, Ventricular | Phase 2 | Status: COMPLETED